At the very core of our technology, we employ a successful form of machine learning called deep learning (a.k.a. artificial neural networks). These models are able to discern between normal and abnormal tissue patterns with unprecedented accuracy, accelerating and improving the medical workflow
We provide several solutions for clinical diagnostics that reduce workflow inefficiencies by streamlining the process of pathological examination, improving its overall quality, and reducing its cost
Our current product offer focuses on breast and prostate cancer diagnosis, and we are quickly expanding it to applications involving colorectal, lung and kidney tissue
We have designed specific solutions for the Life Sciences industry in order to identify novel pathology-based biomarkers that can accelerate drug development
We offer a highly interoperable platform (cloud or on-premise), with a focus on ISO-13485 certification, competitively priced, and ready to accommodate any size of workload at global scale
Aiosyn raises EUR 2 million to develop AI-powered algorithms to support pathologists with clinical diagnostics21 December 2022
Nijmegen, the Netherlands – Aiosyn is developing a diagnostics platform that uses artificial intelligence to support pathologists with more accurate and efficient clinical diagnostics.